

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

Assignment ID: PATI203369

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Wolfgang Richter	01/19/2023
Muhammad Abbas	01/19/2023
Lutz Weber	01/19/2023
Amit Kumar	01/19/2023
<b>RECEIVING PARTY DATA</b>	
<b>Company Name:</b>	ANIXA BIOSCIENCES, INC.
<b>Street Address:</b>	3150 Almaden Expressway, Suite 250
<b>City:</b>	San Jose
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	95118
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	18157293
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	2023712540
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(202)371-2600
<b>Email:</b>	MGROSS@sternekessler.com,smcdonough@sternekessler.com
<b>Correspondent Name:</b>	Michael F. Gross III
<b>Address Line 1:</b>	1101 K Street, N.W.
<b>Address Line 4:</b>	Washington, DISTRICT OF COLUMBIA 20005
<b>ATTORNEY DOCKET NUMBER:</b>	4984.0040001
<b>NAME OF SUBMITTER:</b>	Stephanie McDonough
<b>SIGNATURE:</b>	Stephanie McDonough
<b>DATE SIGNED:</b>	05/01/2024
<b>Total Attachments: 12</b>	
source=2024-05-01-Assignment-4984-0040001#page1.tif	
source=2024-05-01-Assignment-4984-0040001#page2.tif	
source=2024-05-01-Assignment-4984-0040001#page3.tif	

source=2024-05-01-Assignment-4984-0040001#page4.tif  
source=2024-05-01-Assignment-4984-0040001#page5.tif  
source=2024-05-01-Assignment-4984-0040001#page6.tif  
source=2024-05-01-Assignment-4984-0040001#page7.tif  
source=2024-05-01-Assignment-4984-0040001#page8.tif  
source=2024-05-01-Assignment-4984-0040001#page9.tif  
source=2024-05-01-Assignment-4984-0040001#page10.tif  
source=2024-05-01-Assignment-4984-0040001#page11.tif  
source=2024-05-01-Assignment-4984-0040001#page12.tif

## ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, the undersigned inventors: **Wolfgang Richter, Muhammad Abbas, Lutz Weber, and Amit Kumar**, hereby sell and assign to **Anixa Biosciences, Inc.**, a Delaware corporation, having an office at 3150 Almaden Expressway, Suite 250, San Jose, California, United States of America, (hereinafter "Assignee") his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world.

(a) in the invention(s) known as **CYSTEINE PROTEASE INHIBITORS AND METHODS OF USE THEREOF** for which an application for patent was filed on January 21, 2022 (also known as United States Application No. 63/301,847), in any and all non-provisional applications therefrom, in any and all Letters Patent(s) granted from such non-provisional applications, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

This Assignment may be executed in counterparts, each of which will be deemed an original, but all of which together will be deemed to be one and the same Assignment. A signed copy of this Assignment delivered by e-mail will be deemed to have the same legal effect as delivery of an original signed copy of this Assignment.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: January 13<sup>th</sup>, 2023

Signature of Inventor: \_\_\_\_\_

Wolfgang Richter

Date: \_\_\_\_\_

Signature of Inventor: \_\_\_\_\_

Muhammad Abbas

Date: \_\_\_\_\_

Signature of Inventor: \_\_\_\_\_

Lutz Weber

Date: \_\_\_\_\_

Signature of Inventor: \_\_\_\_\_

Amit Kumar

**SIGNED on behalf of the ASSIGNEE.**

**Amgen Biosciences, Inc.**

**Signature:** \_\_\_\_\_

**Typed Name:** \_\_\_\_\_

**Title:** \_\_\_\_\_

**Date:** \_\_\_\_\_

19510001

## ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, the undersigned inventors: **Wolfgang Richter, Muhammad Abbas, Lutz Weber, and Amit Kumar**, hereby sell and assign to **Anixa Biosciences, Inc.**, a Delaware corporation, having an office at 3150 Almaden Expressway, Suite 250, San Jose, California, United States of America, (hereinafter "Assignee") his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **CYSTEINE PROTEASE INHIBITORS AND METHODS OF USE THEREOF** for which an application for patent was filed on January 21, 2022 (also known as United States Application No. 63/301,847), in any and all non-provisional applications therefrom, in any and all Letters Patent(s) granted from such non-provisional applications, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.


The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

This Assignment may be executed in counterparts, each of which will be deemed an original, but all of which together will be deemed to be one and the same Assignment. A signed copy of this Assignment delivered by e-mail will be deemed to have the same legal effect as delivery of an original signed copy of this Assignment.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Wolfgang Richter

Date: 19.01.2023 Signature of Inventor:   
Muhammad Abbas

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Lutz Weber

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Amit Kumar

## ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, the undersigned inventors: **Wolfgang Richter, Muhammad Abbas, Lutz Weber, and Amit Kumar**, hereby sell and assign to **Anixa Biosciences, Inc.**, a Delaware corporation, having an office at 3150 Almaden Expressway, Suite 250, San Jose, California, United States of America, (hereinafter "Assignee") his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **CYSTEINE PROTEASE INHIBITORS AND METHODS OF USE THEREOF** for which an application for patent was filed on January 21, 2022 (also known as United States Application No. 63/301,847), in any and all non-provisional applications therefrom, in any and all Letters Patent(s) granted from such non-provisional applications, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.


The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

This Assignment may be executed in counterparts, each of which will be deemed an original, but all of which together will be deemed to be one and the same Assignment. A signed copy of this Assignment delivered by e-mail will be deemed to have the same legal effect as delivery of an original signed copy of this Assignment.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Wolfgang Richter

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Muhammad Abbas

Date: January 19, 2023 Signature of Inventor:   
Lutz Weber

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Amit Kumar

SIGNED on behalf of the ASSIGNEE,

Anixa Biosciences, Inc.

Signature: \_\_\_\_\_

Typed Name: \_\_\_\_\_

Title: \_\_\_\_\_

Date: \_\_\_\_\_

19518288.1

## ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, the undersigned inventors: **Wolfgang Richter, Muhammad Abbas, Lutz Weber, and Amit Kumar**, hereby sell and assign to **Anixa Biosciences, Inc.**, a Delaware corporation, having an office at 3150 Almaden Expressway, Suite 250, San Jose, California, United States of America, (hereinafter "Assignee") his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **CYSTEINE PROTEASE INHIBITORS AND METHODS OF USE THEREOF** for which an application for patent was filed on January 21, 2022 (also known as United States Application No. 63/301,847), in any and all non-provisional applications therefrom, in any and all Letters Patent(s) granted from such non-provisional applications, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.


This Assignment may be executed in counterparts, each of which will be deemed an original, but all of which together will be deemed to be one and the same Assignment. A signed copy of this Assignment delivered by e-mail will be deemed to have the same legal effect as delivery of an original signed copy of this Assignment.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Wolfgang Richter

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Muhammad Abbas

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Lutz Weber

Date: 1/18/23 Signature of Inventor:   
Amit Kumar

SIGNED on behalf of the ASSIGNEE,

Anixa Biosciences, Inc.

Signature: \_\_\_\_\_

Typed Name: \_\_\_\_\_


Title: \_\_\_\_\_

Date: \_\_\_\_\_

19518288.1

SIGNED on behalf of the ASSIGNEE,

Anixa Biosciences, Inc.

Signature: \_\_\_\_\_

Typed Name: Michael J. Catelani

Title: President, COO & CFO

Date: January 20, 2023

19518288.1